JCJacob Y. Cao

Jacob Y. Cao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jacob Y. Cao has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Fontan pathway diameter in adults undergoing exercise catheterization: Association with hemodynamics, exercise capacity, and liver scores

    by Jacob Y. Cao, Alexander C. Egbe, C. Charles Jain, Christopher Francois, Patrick S. Kamath, Yves D'UDekem, David Celermajer, Rachael Cordina, William R. Miranda


  • Can Australia afford the costs of cardiology guidelines? True costs and strategies for reduction

    by Jacob Y. Cao, David S. Celermajer

    Aim: To estimate the 10‐year Australian healthcare system cost of full implementation of evidence‐based guidelines across five common cardiovascular conditions. Background: Healthcare spending in Australia continues to rise as the population ages and treatment options become increasingly advanced and costly. However, assessment of cost remains conspicuously absent from national and international clinical guidelines, and the implications of such costs for the equity and sustainability of healthcare have not been evaluated in the Australian context. Methods: Using national population estimates and Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) data, we modelled the projected 10‐year cost of full guideline implementation for all eligible or indicated Australians across five common cardiovascular conditions: dyslipidaemia, hypertension, obesity, type 2 diabetes with heart failure or chronic kidney disease, and atrial fibrillation/flutter. These costs were compared against PBS/MBS expenditure from 2024 to 2025. Results: In total, the projected 10‐year cost for only these five cardiovascular conditions is estimated at $45–50 billion (at 2025 prices), which is 3.4–3.9 times higher than the current national expenditure for these conditions. This also highlights the poor uptake of, or access to, evidence‐based care among certain Australian populations. Conclusions: Our analysis highlights the complex balance between efficacy, cost and equity in healthcare. We propose two practical strategies to address these challenges: embedding cost‐effectiveness analyses into guideline formulation and promoting greater use of generic medications. Through these measures, we hope to prioritise cost‐effective, evidence‐based care and make it accessible to all Australians, while maintaining the long‐term financial sustainability of the healthcare system.

  • Adults with Fontan circulation: prognostic value of exercise pulmonary vascular resistance index

    by Jacob Y Cao, Alexander C Egbe, Nick Olsen, C Charles Jain, Barry A Borlaug, Yogesh N V Reddy, Heidi C Connolly, David Celermajer, Rachael Cordina, William R Miranda

    Background and Aims: Decrease in pulmonary vascular resistance (PVR) during exercise confers favourable prognosis in biventricular physiology, but its role in Fontan circulation remains unknown. This study aimed to evaluate the prognostic value of PVR index (PVRI) response to exercise in adults post-Fontan palliation. Methods: Retrospective cohort of 88 adults (age ≥18 years) post-Fontan undergoing exercise (supine cycling) cardiac catheterization. Patients were categorized into absence (n = 23) or presence (n = 65) of exercise-induced reduction in PVRI. The clinical endpoint was a composite of death or transplantation. Results: Age at catheterization was 32.2 ± 8.8 years, and 45.5% were female. Resting and exercise PVRI were 1.9 ± 0.9 and 1.2 (interquartile range [IQR] 0.8–2.1) WU·m2, respectively. Clinical, biochemical and echocardiographic parameters were not associated with PVRI response to exercise. During a follow-up of 2.2 ± 1.4 (IQR 1.2–2.6) years, resting PVRI was not associated with the clinical endpoint (hazard ratio [HR] 0.95 per WU·m2, 95% confidence interval [CI] 0.52–1.74; P = 0.86), whereas exercise PVRI was (HR 2.15 per WU·m2, 95% CI 1.24–3.73; P = .007). Exercise PVRI remained predictive of outcomes after adjusting for exercise pulmonary artery wedge pressure (HR 2.08 per WU·m2, 95% CI 1.19–3.62; P = .01) or clinical risk factors individually. Two-year event-free survival was lower in the no PVRI reduction than in the reduction group (67% vs 95%; P < .001). Conclusions: In adults post-Fontan, PVRI response to exercise is a robust predictor of clinical outcomes and offers additive prognostic information beyond resting invasive haemodynamic data and clinical risk factors, underscoring the importance of invasive exercise testing in this population.


  • Passive Leg Raise Does Not Unmask Diastolic Dysfunction in Adults With Fontan Circulation

    by Jacob Y. Cao, C. Charles Jain, Alexander C. Egbe, Barry A. Borlaug, Yogesh N.V. Reddy, David Celermajer, Rachael Cordina, William R. Miranda

  • Open Access

    Noninvasive Evaluation of Ventricular Filling Pressure and Pulmonary Vascular Reserve in Adults With Fontan Circulation

    by Jacob Y. Cao, C. Charles Jain, Alexander C. Egbe, Yogesh N. V. Reddy, Clare O'DOnnell, David Baker, David Celermajer, William Miranda, Rachael Cordina

    Background: Exercise cardiac catheterization is the gold standard for diagnosing diastolic dysfunction and impaired pulmonary reserve in patients with Fontan circulation. The diagnostic value of noninvasive parameters is unclear. Methods: Patients who underwent simultaneous exercise hemodynamic evaluation and peripheral venous pressure (PVP) measurement were included. Echocardiographic surrogates for ventricular filling pressure were compared with invasive measures. Diastolic dysfunction was defined invasively as either resting pulmonary artery wedge pressure ≥12 mm Hg or exercise pulmonary artery wedge pressure >20 mm Hg. Results: Twenty‐nine patients were included. Age at catheterization was 34±9 years. Atrioventricular valve systole‐to‐diastole duration ratio (S/D) and resting PVP were significant predictors of resting pulmonary artery wedge pressure (S/D: β=0.71 per 0.1 S/D [95% CI, 0.16–1.25]; P =0.01; PVP: β=0.68 per mm Hg [95% CI, 0.41–0.96]; P 2 per mm Hg/100 mL per min [95% CI, 0.08–0.64]; P =0.01). Conclusions: This study presents a simple, noninvasive approach for evaluating diastolic function and pulmonary vascular reserve in patients with a Fontan circulation.


  • Open Access

    Beyond just survival: updates on adult congenital heart disease care

    by Jacob Y Cao, David Baker, Rachael Cordina, David Celermajer

    Survival into adulthood is now the norm for individuals born with congenital heart disease, with over 90% of children reaching adult life. Yet for many, particularly those with complex lesions, childhood intervention does not equate to a cure. Adults with congenital heart disease (ACHD) face ongoing risks of haemodynamic complications, end-organ dysfunction, and premature morbidity. In this review, we present recent advances in ACHD care across five domains: lifelong care models, diagnostic techniques, management strategies, genetic and precision medicine, and machine learning. We highlight the pivotal role of specialized, multidisciplinary care in improving outcomes, and the need for structured transition programmes to ensure continuity from paediatric to adult services. Emerging priorities include reproductive counselling, exercise prescription, and psychosocial support. Advances in cardiovascular magnetic resonance imaging, electrophysiological mapping, and four-dimensional flow imaging now offer unprecedented anatomical and haemodynamic insights. Recent trials have demonstrated encouraging results for novel heart failure therapies and pulmonary vasodilators in lesion-specific subgroups, while transcatheter technologies continue to expand therapeutic options for patients with complex anatomy. Genetic testing and machine learning are beginning to reshape risk stratification and workflow efficiency, though challenges remain in their implementation. As this population ages and acquires new comorbidities, care models must evolve to move beyond just survival, but towards improving quality of life, preserving organ function, and anticipating future needs. This review aims to support clinicians and researchers in meeting these challenges and advancing the next era of ACHD care.

  • Open Access

    Unifying FALD assessment—A call to arms

    by Jacob Y. Cao, Rachael Cordina, Avik Majumdar


  • Prognostic Value of Main Pulmonary Artery Diameter in Pulmonary Arterial Hypertension

    by Jacob Y. Cao, Rita-Maria Abdo, Nelson Wang, Nick Olsen, Kate Kearney, Kirby Wong, Edmund Lau, David Celermajer, Eugene Kotlyar, Rachael Cordina


  • Open Access

    Ventricle-specific myocardial protein and metabolite characterisation in healthy humans, with differential regulation in end-stage cardiomyopathies

    by Benjamin Hunter, Mengbo Li, Benjamin L. Parker, Yen Chin Koay, Dylan J. Harney, Evangeline Pearson, Jacob Cao, Gavin T. Chen, Oneka Guneratne, Gordon K. Smyth, et al.

    Background The left and right ventricles of the human heart are functionally and developmentally distinct such that genetic or acquired insults can cause dysfunction in one or both ventricles resulting in heart failure. The left ventricle is most clinically relevant in research as its dysfunction is the most dominant cause of heart failure whereby right ventricular involvement can exacerbate the condition. However, the molecular composition of the left ventricular adult human myocardium relative to the right ventricle in health and in heart failure has yet to be thoroughly explored. Methods We performed unbiased quantitative mass spectrometry analyses on the myocardium of pre-mortem cryopreserved non-diseased human hearts to compare the proteome (n = 27) and metabolome (n = 25) between the normal left and right ventricles. We then characterised the proteome and metabolome of the left and right ventricles within end-stage dilated cardiomyopathy (n = 14 and 13) and ischaemic cardiomyopathy (n = 19-17), respectively. All analyses featured a mix of paired and unpaired samples. Intra-condition comparative analyses were performed to identify differences of molecular abundance between the ventricles, and intra-ventricular analyses were performed between sexes of non-diseased hearts. Novel and innovative techniques were used to merge datasets, increasing the sample size and statistical power. KEGG and Gene Ontology databases were used to perform enrichment analyses and inform metabolic trends. Results Constituents of gluconeogenesis, glycolysis, lipogenesis, lipolysis, fatty acid catabolism, the citrate cycle and oxidative phosphorylation were down-regulated in the non-diseased left ventricle, while glycogenesis, pyruvate and ketone metabolism were up-regulated. Inter-ventricular significance of these metabolic pathways was then found to be diminished within end-stage dilated cardiomyopathy and ischaemic cardiomyopathy, while heart failure-associated pathways were increased in the left ventricle relative to the right within ischaemic cardiomyopathy, such as fluid sheer-stress, increased glutamine to glutamate ratio, and down-regulation of contractile proteins, indicating a left ventricular pathological bias. Conclusions The inter-ventricular molecular analyses within this study aides to fill a critical gap in our understanding of the metabolic differences between the human left and right ventricular myocardium and may be used to inform future therapeutic targets for heart failure processes in one or both the ventricles.


  • Fontan operation at less than 3 years of age is not a risk factor for long-term failure

    by Jacob Y Cao, Supreet P Marathe, Diana Zannino, David S Celermajer, Robert N Justo, Nelson Alphonso, Yves D’uDekem, David S Winlaw

    The age at which the Fontan operation is performed varies globally. Over the last decade, the median age of patients having the Fontan in Australia and New Zealand has been 4.6 years, including 6% of patients younger than 3 years. Long-term outcomes of an early Fontan operation are unclear and are described in this study. Patients from the Australian and New Zealand Fontan Registry were grouped by age at Fontan. A Fontan before 3 years (early Fontan) was compared to the combined second and third quartiles by age at surgery in the Registry (3.6–6.1 years; control). Outcomes included Fontan failure (death, transplant, New York Heart Association functional group III/IV heart failure, Fontan takedown or conversion, protein losing enteropathy and plastic bronchitis), arrhythmias, thromboembolism and reinterventions. A total of 191 patients who had early Fontan operations were compared to 781 controls. Profound or progressive cyanosis was noted more frequently in the early than in the control group (63% vs 23%; P < 0.001). The early group was followed up for a median 22.1 years. The incidence of long-term failure was similar between the 2 groups (early, 1.08 failures per 100 patient-years of follow-up vs control, 0.99; log-rank P = 0.79). Adjusted for risk factors, early age at Fontan was not a risk factor for long-term failure [hazard ratio (HR) 1.16, 95% confidence interval (CI) 0.77–1.76; P = 0.48], new-onset arrhythmia (HR 0.93, 95% CI 0.63–1.39; P = 0.73), thromboembolism (HR 0.50, 95% CI 0.28–0.91; P = 0.024) or reintervention (HR 1.08, 95% CI 0.80–1.45; P = 0.62). Having the Fontan operation at an early age was not a risk factor for short- or long-term adverse outcomes in our cohort.